KR20210146352A - 안구 질환 치료용 조성물 및 방법 - Google Patents

안구 질환 치료용 조성물 및 방법 Download PDF

Info

Publication number
KR20210146352A
KR20210146352A KR1020217034683A KR20217034683A KR20210146352A KR 20210146352 A KR20210146352 A KR 20210146352A KR 1020217034683 A KR1020217034683 A KR 1020217034683A KR 20217034683 A KR20217034683 A KR 20217034683A KR 20210146352 A KR20210146352 A KR 20210146352A
Authority
KR
South Korea
Prior art keywords
seq
peptide
unit dose
salt
abu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217034683A
Other languages
English (en)
Korean (ko)
Inventor
니란잔 비. 판디
Original Assignee
아스클리픽스 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스클리픽스 테라퓨틱스, 인크. filed Critical 아스클리픽스 테라퓨틱스, 인크.
Publication of KR20210146352A publication Critical patent/KR20210146352A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020217034683A 2019-03-26 2020-03-26 안구 질환 치료용 조성물 및 방법 Pending KR20210146352A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962824017P 2019-03-26 2019-03-26
US62/824,017 2019-03-26
PCT/US2020/024972 WO2020198481A1 (en) 2019-03-26 2020-03-26 Compositions and methods for treating ocular disease

Publications (1)

Publication Number Publication Date
KR20210146352A true KR20210146352A (ko) 2021-12-03

Family

ID=72609544

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217034683A Pending KR20210146352A (ko) 2019-03-26 2020-03-26 안구 질환 치료용 조성물 및 방법

Country Status (12)

Country Link
US (1) US12540171B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946418A4 (cg-RX-API-DMAC7.html)
JP (1) JP7650074B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210146352A (cg-RX-API-DMAC7.html)
CN (1) CN113710264A (cg-RX-API-DMAC7.html)
AU (1) AU2020248438A1 (cg-RX-API-DMAC7.html)
CA (1) CA3134816A1 (cg-RX-API-DMAC7.html)
EA (1) EA202192607A1 (cg-RX-API-DMAC7.html)
IL (1) IL286625A (cg-RX-API-DMAC7.html)
MX (1) MX2021011727A (cg-RX-API-DMAC7.html)
WO (1) WO2020198481A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107235B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
CN117126233A (zh) * 2022-05-20 2023-11-28 杭州禾泰健宇生物科技有限公司 一种类肽化合物及其应用
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2015781A4 (en) * 2005-09-12 2009-12-23 Univ Johns Hopkins COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF
EP2649095B1 (en) * 2010-12-10 2021-10-06 Aleksander S. Popel Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
JP6470740B2 (ja) * 2013-06-07 2019-02-13 ザ ジョンズ ホプキンス ユニバーシティ 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム
CN108883150A (zh) 2015-11-19 2018-11-23 阿斯克雷佩西治疗公司 具有抗血管生成、抗淋巴管生成以及消水肿性质的肽和纳米粒子制剂
MX2019003895A (es) * 2016-10-04 2019-10-07 Asclepix Therapeutics Inc Compuestos y metodos para activar la señalizacion tie2.
US20200179285A1 (en) * 2017-05-08 2020-06-11 The Johns Hopkins University Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
EP3661536A4 (en) * 2017-08-03 2021-07-21 Asclepix Therapeutics, Inc. PROCESS FOR IDENTIFICATION AND MANUFACTURING OF PHARMACEUTICAL INGREDIENTS FOR ACTIVATING A TIE2 RECEPTOR

Also Published As

Publication number Publication date
AU2020248438A1 (en) 2021-10-28
ZA202107235B (en) 2023-10-25
WO2020198481A1 (en) 2020-10-01
CA3134816A1 (en) 2020-10-01
EP3946418A4 (en) 2023-02-22
US12540171B2 (en) 2026-02-03
JP7650074B2 (ja) 2025-03-24
EA202192607A1 (ru) 2022-03-03
US20230054032A1 (en) 2023-02-23
CN113710264A (zh) 2021-11-26
IL286625A (en) 2021-12-01
MX2021011727A (es) 2022-01-24
JP2022527276A (ja) 2022-06-01
EP3946418A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
US11738064B2 (en) Pharmaceutical composition for preventing and treating eye diseases, containing as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
US11180551B2 (en) Humanized monoclonal antibodies that target VE-PTP (HPTP-beta)
ES2390676T3 (es) Método para el tratamiento de enfermedades neovasculares intraoculares
KR20120130752A (ko) 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법
EP2766044A1 (en) Treatment of ocular disease
JP2018502095A (ja) 眼疾患治療のペプチド及びこれを含む眼疾患治療用組成物
US12540171B2 (en) Compositions and methods for treating ocular disease
CA3165887A1 (en) Use of fusion protein in treatment of age-related macular degeneration
CA3171266A1 (en) Norrin regulation of plasmalemma vesicle-associated protein and use to treat macular degeneration
Smith et al. Therapeutic monoclonal antibodies and fragments: Ranibizumab
WO2012013110A1 (zh) 具有抑制血管生成活性的多肽
KR20140130725A (ko) 트롬빈 유래 펩타이드를 포함하는 망막증 또는 녹내장 치료용 조성물
WO2026036282A1 (en) Multispecific fusion proteins targeting angiogenic factors
WO2025054768A1 (en) Multispecific fusion proteins targeting angiogenic and inflammatory factors
WO2026040746A1 (en) Multispecific fusion proteins targeting angiogenic and inflammatory factors
EP2772498B1 (en) Polypeptides inhibiting neovascularization and uses thereof
CN121194795A (zh) 膜联蛋白a5蛋白质与抗vegf药剂作为组合疗法用于治疗黄斑水肿或视网膜静脉阻塞
CN119907677A (zh) 在治疗黄斑水肿或视网膜静脉阻塞中使用的单体膜联蛋白a5

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000